Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rabies vaccine purified chick embryo cell (PCECV) is an inactivated viral vaccine used for the prevention of rabies in humans. It is produced by propagating the rabies virus (typically the Flury-LEP or Pittman Moore strain) in primary chick embryo fibroblast cell cultures. The harvested virus is inactivated using beta-propiolactone and subsequently purified and concentrated through zonal centrifugation. PCECV is indicated for both pre-exposure prophylaxis (PrEP) in individuals at high risk of rabies exposure and post-exposure prophylaxis (PEP) following contact with a potentially rabid animal. It is administered via intramuscular or intradermal injection and works by inducing the production of virus-neutralizing antibodies. Major brands include RabAvert and Rabipur, which are currently owned by Bavarian Nordic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies vaccine purified chick embryo cell.